Adverse events that occurred in at least @ % of patients in either teriflunomide group and with an incidence that was at least @ % higher than that with placebo were increased alanine aminotransferase ( @ -LSB- @ % -RSB- of @ patients in the @ mg group , @ -LSB- @ % -RSB- of @ in the @ mg group vs @ -LSB- @ % -RSB- of @ in the placebo group ) , hair thinning ( @ -LSB- @ % -RSB- and @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) , diarrhoea ( @ -LSB- @ % -RSB- and @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) , paraesthesia ( @ -LSB- @ % -RSB- and @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) , and upper respiratory tract infection ( @ -LSB- @ % -RSB- and @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) .